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In the past, asthma was considered mainly as a childhood disease. However, asthma is an important cause of morbidity
and mortality in the elderly nowadays. In addition, the burden of asthma is more significant in the elderly than in their
younger counterparts, particularly with regard to mortality, hospitalization, medical costs or health-related quality of life.
Nevertheless, asthma in the elderly is still been underdiagnosed and undertreated. Therefore, it is an imperative task to
recognize our current challenges and to set future directions. This project aims to review the current literature and
identify unmet needs in the fields of research and practice for asthma in the elderly. This will enable us to find new
research directions, propose new therapeutic strategies, and ultimately improve outcomes for elderly people with
asthma. There are data to suggest that asthma in older adults is phenotypically different from young patients, with
potential impact on the diagnosis, assessment and management in this population. The diagnosis of AIE in older
populations relies on the same clinical findings and diagnostic tests used in younger populations, but the
interpretation of the clinical data is more difficult. The challenge today is to encourage new research in AIE but to use
the existing knowledge we have to make the diagnosis of AIE, educate the patient, develop a therapeutic approach to
control the disease, and ultimately provide a better quality of life to our elderly patients.Introduction
We are in an unprecedented era of rapid aging of the
global population. Demographic projections estimate that
the number of elderly people will double in many regions
by 2030 [1]. In the past, asthma was considered
mainly as a childhood disease; however, recent epide-
miologic studies have indicated that asthma is highly
frequent in the elderly population with its prevalence
ranging from 4.5% to 12.7% [2-15]. In addition, the
burden of asthma is more significant in the elderly
than in their younger counterparts, particularly with
regard to mortality, hospitalization, medical costs or
health-related quality of life [15-20]. Nevertheless,
asthma in the elderly (AIE) is still been underdiag-
nosed and undertreated [5,21-23].* Correspondence: anahi.yanez@inaerargentina.org
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unless otherwise stated.Notably, AIE may be considered a late-onset disease
[14-23]. The French elderly population cohort 3C study,
reported that asthma incidence among the elderly was
3.0/1,000 person-year [14]. In Italian general population
surveys, the asthma incidence rate after 40 yrs old was
2.27/1,000 person-year, which was increasingly higher
with aging from the third decade of life [24]. Along
with this, AIE might have a different pathophysiology
than in childhood disease, resulting from complex in-
teractions with various factors such as aging-related
lung and immune alterations, epigenetic factors, envir-
onmental exposures, microbial triggers, or various comor-
bidities [19].
However, our understanding of this ‘old but new’ disease
is still not complete. Prior knowledge was mostly based on
experimental or clinical studies targeted for allergic or
Th2-mediated asthma, which is not a predominant feature
in AIE [19]. Clinical studies for asthma treatment have
often excluded elderly subjects [23]. Even epidemiologic
observational studies have been scarce, which wouldtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nature or pathophysiology.
Therefore, it is an imperative task to recognize our
current challenges and to set future directions. The pri-
mary aim of the present World Allergy Organization
project is to review the current literature and identify
unmet needs in the fields of research and practice for
AIE. This will enable us to find new research directions,
propose new therapeutic strategies, and ultimately improve
outcomes for elderly people with asthma.
Life expectations, lifespan and maximum survival
From the perspective of studying aging, there is a signifi-
cant difference between average and maximum life span.
The average life span is the average age reached by
members of a given population, and life expectancy is
the number of years an individual can expect to live. On
the other hand, the maximum life span refers to a measure
of the maximum amount of time one or more members
of a population has been observed to survive between
birth and death [19].
Over the past decades, with the introduction of mod-
ern sanitation, refrigeration and other public health mea-
sures including vaccination, antibiotics, and aggressive
cardiovascular preventive as well as surgical procedures,
there has been an increase in average life span [25]. Early
deaths have been diminished and more individuals are
reaching old age. In the United States today, life expect-
ancy now approaches 80 years [26]. However, the max-
imum life span, which is 122 years old, has remained
unchanged by the public health initiatives mentioned
above [19].
Average life span is what concerns public health officials
and health care providers but for those studying the biol-
ogy of aging, it is maximum survival that is the focus of
greatest attention. This maximum is believed to provide a
more meaningful indicator of the underlying rate of aging
because the average life span may be prolonged entirely
because of an optimization of the maintenance conditions
rather than a slowdown of the rate of aging. It is worth-
while to note that it has been estimated that if athero-
sclerosis and cancer were eliminated from the population
as a cause of death, about ten years would be added to
the average life span, yet there would be no change in
maximum life span [27].
Although several theories have been proposed, none
suffice to account for the complexities of aging. Life span
is finite and varies generally from species to species and
much less so within species. Variations in maximum life
span among different species are often associated with
differences in the metabolic rates of oxygen consumption,
metabolic potential (estimated as the total amount of
energy consumed per gram of body weight during the
life-span), and the level of oxidative stress [19].A causal mechanism of aging, implicating the endogen-
ously generated oxygen free radicals as the agents of
damage, was first proposed by Harman in 1956 [28].
Although experimental augmentation of antioxidant de-
fenses tends to enhance resistance to induced oxidative
stress, such manipulations are generally ineffective in
the extension of life [29]. More recently, in a major
conceptual shift, reactive oxygen species have been
found to be physiologically vital for signal transduction,
gene regulation, and redox regulation, among others,
implying that their complete elimination would be
harmful. An alternative notion, termed the "redox stress
hypothesis," proposes that aging-associated functional
losses are primarily caused by a progressive pro-oxidizing
shift in the redox state of the cells, which leads to the
over-oxidation of redox-sensitive protein thiols and the
consequent disruption of the redox-regulated signaling
mechanisms [29].
Three regimes are known to extend the maximum life
span of animals: (i) lowered ambient temperature in
poikilotherms (cold-blooded animals) and hibernating
mammals and (ii) a decrease in physical activity in poi-
kilotherms, both of which decrease metabolic rate, and
(iii) caloric restriction [19].
Caloric restriction is now being increasingly used as a
model regimen for understanding the basic mechanisms
of aging, primarily because it causes an unambiguous,
robust, and reproducible extension of maximum life span
and delays many, although not all, age-associated biochem-
ical, physiological, and behavioral changes [19].
The extension of maximum life span by caloric restriction
in mammals and hypometabolic states in poikilotherms,
point toward the involvement of environmental-genetic
interactions in the process of longevity. However, the exist-
ence of specific gene products, that initiate deleterious
alterations in the latter part of life, has not as yet been
demonstrated [29]. As stated by Hayflick [30], genes do
not directly drive the aging process, rather they indirectly
modulate the potential life span by specifying a certain
level of physiological fitness, determined by the efficiency
of functions such as repair, turnover and replacement.
Accordingly, the progression of senescent deterioration
can be envisioned to be mainly dependent upon the
genome-controlled efficiency of the physiological systems
to maintain homeostasis, and the magnitude of the sto-
chastic events that diminish the ability of the organism to
maintain homeostasis. Thus, the pathways/mechanisms
involved in resistance to various types of stress and main-
tenance of bioenergetic capacity and redox homeostasis
may be critical in the evolution of longevity [29].
As of today, there have never been more people, more
elders, and more smokers than ever before in the history
of mankind. The World Health Organization estimates
the ever increasing World population grew to 7.06 billion
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2011 (Figure 1). Most of this growth is occurring in
developing countries [31].
Further, with 1.1 billion there have never been as many
smokers as of today [31]. Finally, the world population is
ageing, with an inverted age- and gender-pyramid struc-
ture soaring (Figure 2), and it is considered that most
babies born since 2000 in many countries (i.e.: France,
Germany, Italy, the UK, the USA, Canada, Japan, and
other countries with long life expectancies) will celebrate
their 100th birthdays [32].
Hence, the numbers of older people with cancer, frac-
tured hips, strokes, and dementia will increase, and many
older people will have multimorbidities. One might think
that this will bring a formidable challenge to many coun-
tries. However, projected increases in health expenditure
as a result of ageing are slight and ageing does not present
a fundamental threat [33].
Asthma is considered a common condition (the most
frequent in children), mostly with mild symptoms at the
population level, and with relatively good individual
prognosis [32].
Individuals with asthma are/will be living the same life
expectancy as those with no asthma, therefore will require
asthma treatment and monitoring for decades. In the
latest Global Burden of Disease update, asthma ranked
14th in the classification of Years Lived with Disability,
and totaled counts of 334 million pople with asthma
worldwide [34].
Impact of AIE
Asthma is a common disease affecting individuals across
the lifespan. Because of increased longevity, the propor-
tion of individuals aged 65 years and older (heretofore
referred to as the elderly) is increasing worldwide. By
2030, elderly subjects will comprise ~20% and ~36% of
the populations of the United States (U.S.) and China,
respectively [35,36]. Given these demographic changes,Figure 1 World Population Growth trends from 1950 and projected tthe fact that asthma is already common in elderly sub-
jects (see below), and the inevitable aging of children
affected by the “asthma epidemic” in the second half of
the 20th century [37], the impact of AIE is expected to
be magnified over the upcoming decades.
Determining the exact prevalence of AIE is made difficult
by barriers including: 1) under-diagnosis due to decreased
perception or under-reporting of symptoms by patients
[21], 2) suboptimal utilization of spirometry and other diag-
nostic tests, 3) misclassification of asthma as chronic
obstructive pulmonary disease (COPD) and vice versa, 4)
failure to recognize asthma in subjects with co-morbidities
such as congestive heart failure or COPD, and 5) exclusion
of elderly subjects from population-based studies of asthma.
In spite of these challenges, current evidence consistently
suggests that asthma is common among elderly subjects.
In two nationwide surveys in the U.S. (conducted using
similar methods), estimates of the prevalence of current
asthma (defined as physician-diagnosed asthma [ever] in
subjects with active disease) in the elderly were 3.6% for
the period comprising 1988 to 1994 [38] and 5.9% for the
period comprising 1980–2004 [39]. In a community-based
cohort study of elderly subjects in the U.S., “definite
asthma” (defined in the same manner as “current asthma”
in the two studies above) and “probable asthma” (defined
as wheezing accompanied by chest tightness or shortness
of breath in the previous year) were each estimated to
be present in 4% of non-smoking elderly participants
without congestive heart failure [21,38-41]. In this study,
estimates of the prevalence of current and “probable”
asthma in all subjects were 11% and 14%, respectively. In
elderly subjects, asthma is more common in women than
in men [39]. The 5-year age- and sex-specific incidence of
new cases of asthma in subjects older than 65 years has
been estimated to be approximately 1 in 1,000 [40].
Compared to children or younger adults, older adults
and/or elderly subjects have greater morbidity and health-
care costs from asthma. In 2012, Tsai et al. published theo 2050.
Figure 2 World Population age-and gender-structure in 1956, 2006 and projected to 2050.
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for emergency department (ED) visits and hospitalizations
between 2006 and 2008 [42]. Among subjects who visited
the ED for asthma, those aged 55 years and older had
higher rates of hospitalization and near-fatal asthma
events, higher hospital charges, longer hospital length
of stay and higher overall mortality than adults aged 18
to 54.9 years (P <0.001 in all cases). Similar findings
were obtained after adjusting for co-morbidities and other
covariates, or after excluding subjects having COPD-
related secondary diagnoses [41]. Charges for ED visits,
hospitalizations, prescription medications and manage-
ment of co-morbidities predictably result in substantial
cost burdens attributable to AIE [18,42].
Older adults (including the elderly) have been shown
to have a higher overall (all-cause) mortality than younger
subjects with asthma in most [42-44,46-48] but not all
[45] published studies. From 2001 to 2003, the estimated
rates of all-cause mortality among subjects with current
asthma in the U.S. were substantially higher in elderly
subjects (~10.5 per 100,000) than in subjects in other age
groups (<2.2 per 100,000 in all cases)6. In the recent study
by Tsai et al. [42], elderly subjects (ages 65 years and
older) had fourfold greater overall mortality than subjects
ages 18 to 64.9 years (odds ratio = 4.1, 95% confidence
interval = 3.1 to 5.5).
The aging lung: the role of the inflammatory,
allergic and infectious process
Structural, cellular and physiologic changes in the
aging lung
Respiratory mechanics
Respiratory mechanics involves an interplay between the
chest wall, lung and diaphragm. Because of simultaneous
changes in the mechanical properties of the lungs and
chest wall and the interdependence of muscle groups,it is difficult to precisely quantify age-related changes
of specific respiratory muscles [49]. Respiratory muscle
strength, particularly that of the diaphragm, can be
assessed by measuring the maximum voluntary ventila-
tion (MVV) and maximum inspiratory pressure (MIP).
MVV is reduced with age [50], and the clinical risks
associated with such changes include diaphragmatic
fatigue and potential ventilatory failure during increased
ventilatory load. MIP is a measure of diaphragmatic
strength and has also been shown to decrease between
the ages of 65 and 85 years [51,52].
Given the similarities between the aging lung and the
lung affected by COPD, some speculate that COPD
actually represents an accelerated lung aging phenotype
[53]. The aging lung mimics emphysema in that both
have enlarged alveoli, decreased surface area for gas
exchange, and decreased elastic recoil, leading to the
term “senile emphysema” that has been used to describe
the normal aging lung. This term is not fully accurate,
however, since the normal aging lung lacks airway wall
destruction and distal duct ectasia classically seen in
emphysema, and the changes of normal aging are more
homogeneous than those of emphysema [54-56]. What is
not clear is whether “senile emphysema” reflects aging-
associated destruction of lung parenchyma or loss of
supporting structures [57]. There is degeneration of the
elastic fibers around the alveolar duct starting around
50 years of age, resulting in enlargement of airspaces.
Dynamic CT imaging has shown emphysematous change
with age [58]. However, a definitive progression to an
emphysema phenotype will never be proven because
this would require serial biopsies over many years.
Cellular
Ultimately, the major effect of aging on the immune sys-
tem may be a shift from naïve to memory lymphocytes
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contributing to low-grade chronic inflammation [59-61].
Although the effects of aging on adaptive immunity have
been studied more extensively (they will be described
later in this chapter), several features of innate immunity
may also change with aging. In animal studies, macro-
phages have been noted to decrease their expression of
toll-like receptors (TLRs), their secretion of cytokines
following activation, and their phagocytic ability. This
decline occurs in parallel with decreasing levels of
macrophage-derived chemokines [59,60]. The effect of
aging on monocyte and macrophage function in humans,
however, remains controversial. Although some studies
suggest that aging does not affect the function of these
cells, others have demonstrated an impaired cytotoxic
effect of aged monocytes [62]. In addition to impaired
function, monocyte/macrophage and lymphocyte recruit-
ment to infected tissue has been shown to be delayed in
elderly individuals based on a study of cutaneous punch
biopsies [63].
Examination of cell types and molecules in the BAL
fluid of older adults supports the theory of low-grade
chronic inflammation in the aging lung. It has been
demonstrated a higher percentage of neutrophils and a
lower percentage of macrophages [64]. This increased
proportion of neutrophils in BAL fluid with age was also
noted in two subsequent studies by Meyer et al. [65,66].
A significant increase in total cell concentration, neutro-
phils, immunoglobulin content, and IL-6 concentration
was observed in the BAL fluid from older adults [65,66].
BAL samples from the older individuals demonstrated
more IL-8, neutrophil elastase, and several antiproteases,
consistent with an increased neutrophil predominance
in these older individuals [67]. These observations sug-
gest that even asymptomatic and clinically normal older
volunteers have altered inflammatory profiles, reflecting
the presence of low-grade inflammation in the lower
respiratory tracts. These alterations include a significant
rise in the number of CD4+ T cells, neutrophils, immu-
noglobulins, and cytokines such as IL-6 and IL-8, as well
as an increase in the release of superoxide anion and
other byproducts of neutrophil activation [65-67].
Physiologic changes
Even in the absence of disease, there is a predictable loss
of lung volume with advancing age. The lungs undergo
growth and maturation approximately to age 20, at which
point maximal function is achieved. Lung function
remains static through the third decade and into the
fourth decade of life, after which a decline in pulmonary
function begins. Most cross-sectional studies show a linear
decline in FEV1 with age, whereas longitudinal studies
show a nonlinear decline with age. The estimated rate of
decline in FEV1 is initially 25–30 ml/yr. starting at age35–40 and can double to 60 ml/yr. after age 70 [68].
However, the actual rate of decline is difficult to assess
as inter-individual variability exceeds the decline reported
based on predictive modeling.
The ratio of FEV1 to FVC is lower in older healthy
people; therefore, the use of a fixed cut like 0.70 or 80% as
the lower limit of normal will result in the over-diagnosis
of obstructive airway disease in older adults [69-73]. Data
collected from the Cardiovascular Health Study have sug-
gested that the lower limit of normal for FEV1/FVC
should be 64% to 56% for persons aged 65 to 85 years, re-
spectively [74]. Finally, the clinical implications of such
age-related decline must be factored in with the maximal
attainable lung function.
Age related changes in adaptive immunity
Changes of lymphocyte function with age
Lymphocytes clearly change with aging. There is a reduc-
tion primarily in thymic function as T cells age, and the
number of naïve lymphocytes in the thymic compartment
as well as in the periphery is significantly reduced with
aging. As a direct consequence, the actual mass of T cells
and B cells probably undergoes at 25% reduction with
aging. The causes of this age associated decline clearly
relate to the decline in the generation of naïve cells
[75,76]. Nave CD4 cells isolated from older humans have
decreased in vitro responsiveness to activation through T
cell receptor pathways, but also through different cytokine
usage and secretion patterns when compared to naïve
CD4 cells taken from young individuals. CD4+ T cells
and loss of function of signaling proteins with aging may
reduce the efficiency of this synaptic activation between
antigen presenting cells and T cell receptors [76,77].
Memory T cells which are long lived and maintained by
homeostatic cytokines remain relatively competent even
into old age, but the numbers of these memory CD4 T
cells are reduced [77]. The differences in B cell activation
as aging occurs may play a potential role in the increase in
significance of autoimmunity and selection on B cell
clones that are not common clones that can lead to
altered autoimmune immunity at the B cell level. B cell
related aging also uncovers a lack of normal responses. It is
also possible that memory B cells that may be maintained
that are of little value in terms of maintaining a protective
vaccination status with reduced T cell activation [78].
The mechanisms of aged lymphocyte dysfunction
Altered expression of chemokines and cytokines via actual
production as well as receptor expression are found in
both human T cells and murine models of aging. Immu-
nosenescence and clonal energy is also a significant con-
tributor to reduction T cell activity in aging individuals.
These senescent T cells escape apoptosis but are unable
to be activated with this normal and standard means of
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of clonal cells that are non responsive and are of very little
use in the terms of host defense and/or maintenance of
vigilance against disease [77,78].
Implications for disease and physiological responses
The fact that aging T cells fail and have reduced function
is of concern for three reasons. The first is inadequate
responses to vaccination as elderly individuals are vacci-
nated receiving pneumovax and other anti pneumonia
agents, some directed at bacteria and some directed at
viruses. The development of an actual significant immune
response is critical in the CD4, CD8 and B cell com-
partments, but the reduction in size and function of
these compartments correlates with difficulty in achieving
proper vaccination and it should be examined in any
elderly individual receiving a vaccination. Hence, the
efficacy of the vaccination process needs to be tested
in those individuals and the revaccination and booster
activities should be put in place of those who make a
less than adequate response to any vaccine. In addition,
the lack of vigilance related to the T cell compartment
through help of NK cells and CD8 T cells is also of
consideration and potential development of both auto-
immune diseases and also hypersensitivity diseases in-
cluding asthma for quite possibly other lung disease
including susceptibility to ARDS with infection and
susceptibility to other viral lung infections [78].
Allergen sensitization in older adults
The role of atopy and asthma in older subjects, unlike in
children and young adults, is not completely understood.
Over 80% of young children with asthma are allergen
sensitized, and atopy in this age group increases disease
morbidity [79,80]. Additionally, atopy plays a critical role
in the inception of asthma in this age group, in particular
during viral infection [23]. However, with increased recog-
nition of asthma in older subjects, our knowledge on
the role of IgE sensitization to antigens and subsequent
exposure to subjects with asthma in this age group is
increasing. It is well established that with increased age,
total serum IgE decreases. This has been demonstrated
in several cross-sectional studies of randomly selected
individuals. For example, the Tucson Epidemiological
Study and the National Health and Nutrition Examination
Survey (NHANES 2005–2006) reported that IgE peaks
by 20 years of age and is lowest after 70 years [81,82].
However, not all studies have not supported this trend.
[83,84]. Additionally, when looking at the prevalence of
allergen-specific IgE, younger populations, including
subjects with and without asthma, tend to have a higher
prevalence of allergen-specific IgE sensitization than in
older groups [83,85]. This has been reported in several
longitudinal studies from cohorts of randomly selectedsubjects from Tucson [85], Nottingham [86], Copenhagen
[87], and in the European Community Respiratory Health
Survey [88].
Although it is generally accepted that antigen-specific
IgE sensitization decreases with age, the prevalence of
older patients with asthma who are atopic is not clearly
established. For many years, asthma in older patients was
characterized as non-atopic or intrinsic [89]. Over the past
two decades, there have been a few reports investigating
older patients with asthma, which have demonstrated that
atopy (defined as IgE-sensitization to at least one antigen)
is not uncommon in this group. The reported percentage
of older patients with atopic versus non-atopic asthma
may depend upon the characteristics of the population
studied. Studies done in non inner- city populations are
variable; suggesting that 28% to 74% of older adults with
asthma are sensitized to at least one antigen [90-93].
However, there aappears to be a higher rate of allergen
sensitization in older patients with asthma compared to
age-matched controls without asthma, suggesting a dif-
ference with asthma [90,92].
Two studies have investigated antigen sensitization
rates to common aeroallergens in older asthmatics from
US inner-city populations. Rogers et al. reported that in
an asthma clinic in New York City , that 60% of sub-
jects > 65 years of age had at least one detectable allergen
specific IgE (including outdoor allergens) and that cock-
roach sensitization was the most prevalent at 47% [94].
Cockroach sensitization was associated with more severe
asthma as determined by airflow limitation and hyperin-
flation. This study did include a group of younger subjects
from the same population for comparison. Another study
done in New York City reported that 41% of subjects over
the age of 60 years with moderate to severe persistent
asthma, were sensitized to at least one antigen, whereas
73% between 18–35 years of age were sensitized [95].
Antigen sensitization developing later in life may contrib-
ute to late onset asthma in some patients [96,97]. In the
Normative Aging Study, which followed subjects over an
extended period of time, those men who developed airway
hyper-responsiveness after 49 years of age were more
likely to have developed recent IgE to cat (23.9% versus
4.4%) compared to age-matched controls [96]. Addition-
ally, approximately 50% of the forty patients in the Tuc-
son Epidemiologic study of obstructive lung diseases who
developed asthma after the age of 60 years were skin prick
positive to at least one antigen, compared with 26% of the
age-matched control population without asthma [90]. In a
study of 21 patients with asthma onset after 65 years of
age, 81% demonstrated a positive skin prick test to at least
one allergen compared to a group of 14 patients develop-
ing asthma before the age of 65 years in whom 57%
were allergen sensitized [96]. A French study recruited
1,485 patients (mean age 73 years) with a diagnosis of
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developing asthma after 65 years of age were sensitized
to at least one antigen by skin prick testing, whereas
60.1% of those developing asthma prior to 21 years of
age were antigen sensitized [91].
The most common aeroallergen to which older patients
with asthma are sensitized is not consistent among
reports, but includes cat [93], dust mites [92,95], and
cockroach [94]. Whether the differences in specific
antigen sensitization are due to socioeconomic status,
geographic location and environmental exposures, is not
well established at the present. An important unanswered
question is, what is the role of allergen exposure in sensi-
tized older patients with asthma on disease pathogenesis
and severity?
There is emerging evidence for Staphylococcal entero-
toxin (SE) sensitization as a major risk factor for adult
asthma [98-100]. Particularly, it is suggested to have rela-
tionships with intrinsic asthma [101], or severe non-atopic
late-onset asthma [102]. In recent GA2LEN surveys,
the prevalence of SE IgE sensitization was 29.3% in the
European adult populations, which was higher than
that of house dust mite (14.9%) [100]. Of note, they
found that the SE sensitization was positively related
to smoking history and aging. As Staphylococcus aur-
eus is a frequent colonizer in the upper airways and
skins, the airway epithelial disruption by repeated smoke
exposure [103] or the reduced cutaneous barrier function
by aging process [104] could contribute to the SE IgE
sensitization. Thus, ‘aging’ could be a predisposing factor
for SE sensitization and also for developing asthma in later
adult life among susceptible subjects. Although there is
still no direct evidence, the collective evidence suggests
the potential contributions of SE sensitization on the
nature of elderly asthma. The atopic condition in the
geriatric age group represents an additional tool in the
diagnostic process and, consequently, in the therapeutic
approach [105].
Immunosenescence and infection
Immunosenescence affects both the innate and adaptive
immunity [106,107]. Major clinical impact of immunose-
nescence is an increased susceptibility to microbes, such
as viral or bacterial infection. The health care cost is
larger for older people than young people as a result, at
least in part, of the increased susceptibility to infectious
diseases and reduced immune responses to vaccination
with aging. For example, older subjects exhibit a higher
mortality rate to influenza viral infection compared to
younger subjects [108]. Therefore, it is important to
understand the impact of aging on the immune system.
In older asthmatics as well as in children, viral respiratory
infection is associated with worsening of asthma control
[109]. In a prospective cohort study among healthy elderlysubjects and high-risk subjects (those with chronic heart
or lung disease), respiratory syncytial virus infection was
observed annually in 3 to 7% of healthy subjects and in 4
to 10% of high-risk subjects. On the basis to the diagnosis
at discharge, RSV infection accounted for 10.6 percent of
hospitalizations for pneumonia, 11.4 percent for chronic
obstructive pulmonary disease, 5.4 percent for congestive
heart failure, and 7.2 percent for asthma [110].
Vaccination is an effective approach to sustain immune
responses and prevent the deterioration of infectious
disease for elderly subjects. In general, commonly used
vaccinations against influenza virus and pneumococcal
pneumonias are effective at preventing the development
of these infectious diseases among the elderly subject
[111,112]. Among asthmatics, vaccination against in-
fluenza virus has been shown to help prevent asthma
exacerbations in children but there is less [113], but less
evidence is present in elderly asthmatics. Pneumococcal
vaccination is recommended in COPD patients, but its
value in adult asthmatic patients is less certain [114].
In summary, the immune system declines with age, and
elderly asthma patients are more prone to airway infection
than younger subjects. However, studies exploring the
association between asthma and infection have mainly
targeted pediatric patients. In the future, clinical and
experimental studies focusing on elderly subjects are
expected to clarify the role of immunosenescence in
the pathophysiology of asthma.
Role of upper airway diseases in elderly asthma
Relationships between asthma and upper airway diseases
have been consistently observed across various age groups
[115-117]. However, the mechanisms of their associations
may be multifactorial, including atopy, microaspiration,
nasopharyngo-bronchial reflex, or systemic pathway [118].
In the past, the role of inhalant allergen sensitization has
been considered as a major factor to predispose the devel-
opment of asthma in subjects with allergic rhinitis [119].
However, rhinitis and asthma in the elderly appear to be
mostly non-atopic but still show significant associations
[120], suggesting the presence of further mechanisms in
the aged population.
With regard to this, recent evidence indicates the
potential roles of chronic rhinosinusitis (CRS) in the
asthma pathogenesis. The GA2LEN surveys found that
late-onset adult asthma was independently associated with
CRS irrespective of nasal allergies [121]. Recent endotype
approaches suggest the specific roles of Staphylococcal
enterotoxin sensitization in the pathogenesis of CRS
subtypes with nasal polyp [122] and severe late-onset
non-atopic adult asthma [102]. These findings may also
be quite relevant to the elderly population, as elderly
asthma is a considerably late-onset disease.
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emphasis on the clinical features of the overlap
between COPD and asthma
Asthma is underdiagnosed in the elderly due to misattri-
bution of symptoms and signs to other diseases common
in the aged, such as COPD or heart disease, or acceptance
of symptoms and limitations as a normal result of
aging. Thus, the clinician must remain more vigilant to
recognize asthma in older patients [123].
Aging influences the symptoms of asthma and the risk
of mortality. This may be due to changes in airway physi-
ology with aging and the decreased response to treatment
[124,125].
Physiology and making the diagnosis of asthma
Lung function decreases with age due to increased stiffness
of the chest wall, reduced respiratory muscle function and
an increase in residual volume from loss of elastic recoil.
The decline in the elasticity of the airway is considered
the major contributor to the increase in fixed airflow
obstruction and work of breathing with age. The result
is a decrease in FEV1/FVC, such that normal elders have
spirometric features suggestive of obstructive lung disease.
Thus, the diagnosis of AIE is challenging, and AIE is
commonly misdiagnosed as COPD resulting in the under-
diagnosis and under-treatment of asthma [126]. Signifi-
cant, irreversible airflow obstruction in older adults is
usually due to COPD, while remodeling or bronchiectasis
with segmental fibrosis is more characteristic of older
adults with asthma. Patients with COPD often have
increased lung volume (air trapping), reduced diffusion
capacity, and emphysematous changes on high resolution
tomographic imaging (often absent on chest radiographs).
When these findings are present, patients with persistent
dyspnea and reduced FEV1 of less than 60% predicted are
more likely to have COPD than AIE [127].
It has been suggested that, overall, the prevalence of
airway hyperresponsiveness increases with age, and there
is a positive correlation between age and airway hyperre-
sponsiveness recruited subjects aged > 65 yrs [128,129].
The clinical significance of these observations lies in
the fact that the elderly population is particularly at risk
of developing persistent airway closure. The important
question is, therefore, whether measurements of airway
hyperresponsiveness are valuable in elderly individuals,
in whom the perception of symptoms may be blunted.
Scichilone et al. propose that assessment of airway
hyperresponsivenes in the elderly should be considered
an additional tool in the diagnostic work-up of subjects
who belong to the at risk group [128].
AIE may also have specific phenotypes. It appears that
age of onset, and thus the duration of asthma, may be
important in delineating at least two such phenotypes:
late-onset asthma (LOA) with onset after middle age,and long-standing asthma (LSA) with onset in childhood
or in early adulthood. Although atopy is commonly asso-
ciated with both phenotypes, allergies and obesity are
commonly associated with LSA, but much less likely to
be associated with LOA [126,127].Clinical features
The symptoms of asthma and COPD are very similar, if
not identical. The major differences are the degree of
reversibility is often greater in asthma and the persistence
of dyspnea is greater in COPD. Both are characterized by
exacerbations which respond to corticosteroids and bron-
chodilators, infections triggering exacerbations, episodic
wheezing, cough with or without mucous production,
improvement with chronic inhaled corticosteroids and
bronchodilators, and decreased exercise tolerance. The
chronic bronchitis phenotype of COPD as opposed to the
emphysematous phenotype is more likely to be confused
with asthma, but the variations of phenotypes in both
diseases confounds simple measures to reliably distinguish
one from another [126,127]. The major distinguishing
clinical features between the two diseases are personal or
family history of atopy and/or asthma with symptoms
starting in childhood being more likely with asthma;
cigarette smoking history and adult onset of symptoms
being more likely in COPD; and increased biomarkers
including fractional exhaled nitric oxide, peripheral and
sputum eosinophil and serum total and specific IgE being
more likely with asthma [95]. However, exceptions are not
unusual, and the LOA phenotype may not exhibit many of
the distinguishing factors for asthma [127].Overlap between COPD, asthma and other diseases with
fixed airflow obstruction
In addition to the diagnostic challenges resulting from
spirometric changes of aging and other disease processes
that share similar clinical presentations, the identi-
fication of triggers for AIE are more difficult to define.
Infections are the most important triggering factors,
similar to COPD [126,127]. Compared to the younger
asthmatic, the role of specific IgE in AIE is decreased,
and a positive family history of asthma is less common,
particularly in the LOA phenotype [95]. In addition, due
to changes in the skin from normal aging and damage
from sun exposure in the elderly, the responses of skin
testing are smaller in induration, have less erythema
and are less consistent. Thus, the interpretation of both
allergen skin tests and in vitro specific IgE testing is
confounded in the elderly [95,130]. Peripheral blood or
airway eosinophilia, characteristic of asthma is useful in
distinguishing COPD from asthma. Also the severity of
upper airway disease is likely to be more significant in
asthma compared to COPD [126,127].
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elderly the source of cough is often multifactorial. The
other conditions or disorders causing cough in older
adults include laryngopharyngeal reflux, pulmonary con-
gestion from heart disease, COPD, angiotensin converting
enzyme inhibitor therapy, airway dryness from Sjögren
syndrome or the drying effects of other medications,
aspiration due to swallowing dysfunction, pulmonary
fibrosis, bronchiolitis or bronchiectasis. Chest imaging
and review of medication lists may be very helpful in
distinguishing these other causes of cough from the
cough from asthma.
A restrictive component of decreased airflow would
suggest pulmonary fibrosis, bronchiectasis, chest wall
restriction from prior surgery or injury, calcification of
costal cartilage or scarring of the lung from prior infection,
or chronic aspiration. Finally, the coexistence of more than
one disease in older adults is more likely, further challen-
ging diagnostic certainty [127]. Given that the prevalence
of smoking in asthmatics mimics the prevalence of smok-
ing in the general population in that country [131], all
asthmatics should have their smoking status assessed, and
offered individualized anti-smoking strategies, both to
improve their asthma and overall health.
Upper airway comorbidities
Whereas younger patients with asthma often suffer from
allergic rhinitis complaints, elderly patients with asthma
often suffer from sinus symptoms, including nasal ob-
struction, loss of smell and facial pain/headache. A recent
Europe-wide epidemiologic study on the prevalence of
chronic rhinosinusitis (CRS) did confirm the well-known
association between allergic rhinitis and early-onset asthma,
but also demonstrated a clear increased risk to suffer
from late-onset asthma in CRS patients [132]. CRS may
be phenotyped as CRS without (CRSsNP) and with nasal
polyps (CRSwNP), based on symptoms (loss of smell is
typical for CRSwNP, headache and facial pain are typical
for CRSsNP), nasal endoscopy (presence of bilateral nasal
polyps) and CT scanning. From those phenotypes, CRSwNP
has a clearly increased risk of asthma comorbidity in
Caucasian populations [133], whereas CRSsNP does not
significantly impact on asthma, but may be associated
with other lower airway disease [134].
Among the group of nasal polyps, esp. the interleukin
(IL)-5 positive endotype, predominantly showing an
eosinophilic inflammation, bears a high risk of asthma
comorbidity (up to 70%). In these patients, serum total
IgE often is increased, independent of the atopic status
of the patient [135]. IgE antibodies to Staphylococcus
aureus superantigens (SE-IgE) can be detected in a large
proportion of these patients, increasing with the severity
of disease [102]; about one third to half of the patients
suffer from upper airway disease, mostly nasal polyposis.SE-IgE antibodies are significantly associated with se-
vere asthma, oral corticosteroid use, hospitalizations
and lung function parameters [102]. SE-IgE antibodies
are also associated with an increased risk of suffering
from asthma in the general European population accord-
ing to an epidemiologic study investigating more than
55000 patients [136].
In elderly patients with asthma, diagnostic means
therefore should include questions on nasal and sinus
symptoms, and a nasal endoscopy and evtl. a CT scan
in case of such symptoms. It is advisable to integrate
the ENT specialist in the management, once CRS cannot
be excluded by the complete lack of nasal symptoms.
Tests in serum may include blood eosinophils, total IgE
and specific IgE abs to SEs also in SPT-negative subjects.
The treatment of the upper airways in these patients
might furthermore support the management of the lower
airways, and therefore should be part of the individual
therapeutic strategy [134].
There is a growing problem of allergic rhinitis in elderly
patients. In an epidemiological study of atopic bronchial
asthma (BA), allergic rhinitis, and atopic dermatitis (AD)
in an elderly Polish population from 16 sites representa-
tive of Polish rural and urban areas, the high prevalence
of allergic rhinitis and BA in younger individuals with
allergies was comparable with those involving groups of
elderly Polish patients [137]. The study used medical
examinations, an original questionnaire, skin-prick testing
(SPT) with common aeroallergens, and serum-specific IgE
assays for diagnosis. Similarly, the prevalence of allergic
rhinitis among persons aged between 60 to 70 years in
Switzerland was around 13-15% [138].
In a study evaluating asthma control in elderly individ-
uals and analyzing the factors that predict poor control,
a retrospective, observational study evaluating 108 elderly
individuals with asthma was conducted [139]. Clinical
data of two groups based on the scores on the asthma
control test (ACT), one with ACT scores ≤19 and the
second group with ACT scores >19 were studied. Comor-
bid conditions were found in more than 80% of the
patients. Allergic rhinitis was most common comorbid
condition (76.9%). In more than one third of the elderly
patients with asthma, the asthma was poorly controlled
characterized by significantly lower asthma quality of life
scores and higher hospitalization rates.
An appropriate assessment and management of upper
airway comorbidities in elderly patients with asthma is
essential for better asthma control and a better quality
of life of the patients.
Association between asthma and comorbidities
Several studies documented that numerous comorbidities
are frequently associated with asthma. Therefore, the
identification of comorbidities must become an integral
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evaluation, not only of the presence of comorbid condi-
tions, is necessary, but we have to ensure that these are
also adequately treated/controlled so that their effect
on asthma is minimized [140].
The AIE was associated with cardiovascular and hyper-
tensive diseases. Also weakly associated with depression,
diabetes mellitus, dyslipidemia, osteoporosis and rhino
sinusitis. In contrast, it was strongly associated with
GORD and, particularly, allergic rhinitis.
Being female slightly increased the association of all
cardio- vascular diseases, mainly heart failure, but not
angina, coronary disease and acute or old myocardial
infarction, with asthma. In males, there was no association
between asthma and acute or old myocardial infarction;
moreover, in males, asthma was not associated with
hypertensive disease. However, in contrast to females,
males presented with an association between asthma and
angina and coronary disease. In females, the association
between diabetes mellitus, dyslipidemia, osteoporosis,
depression, psychiatric disorders and GORD and asthma
was stronger than in males. In males there was no asso-
ciation between asthma and diabetes whereas the asso-
ciation between asthma and allergic rhinitis and rhino
sinusitis was stronger than in females [141].
Management of asthma: pharmacological and
non-pharmacological interventions; asthma
education; and pulmonary rehabilitation
Basically, asthma management in the elderly should follow
the same rules as for younger patients. The main goals are
to achieve asthma control and prevent exacerbations
[138]. In these patients, asthma is under-diagnosed and is
often confounded with other conditions such as COPD
[139]. The evaluation of asthma control/severity may be
more difficult. In addition, patients with AIE may be more
sensitive to the side-effects of medications [142,143]. As
co-morbid conditions are common in this population,
polypharmacy is frequent, thereby increasing the risk of
drug interactions. Treatment is often suboptimal, due
to underassessment of asthma control/severity by the
clinician. Multiple patient factors lead to suboptimal
disease control, including misunderstanding of asthma
as a disease and the treatment regimen, poor adherence
to treatment recommendations, memory problems, and
socioeconomic challenges [142-145]. Regrettably, most
asthma RCTs conducted to date have excluded old adults
and the elderly, so no evidence on efficacy and safety of
respiratory drugs is available. Therefore, most data come
from observational studies.
Acute exacerbation rate in the elderly appears to be
comparable to younger adult asthma, as was reported as
21.6% in recent elderly asthma cohort studies [146].
However, factors related to exacerbations may be moremultifactorial in the elderly, as they have more comorbid-
ity and decreased socioeconomic, cognitive, or physical
capabilities [147]. Therefore, the management of elderly
asthma should include further cares for depression, treat-
ment adherence, or inhaler technique education [146].
Non-pharmacological interventions
Although atopy is less frequent in the elderly, it can still
affect a significant number of patients and environmental
measures should be considered whenever there is relevant
exposure to sensitizers [23,24]. In patients who remain
employed, workplace exposures to irritants or sensitizing
agents should be documented. The current recommenda-
tions on avoidance of respiratory irritants, particularly
cigarette smoke, also apply [138].
Aging is associated with weight gain and a sedentary
lifestyle. Regular exercise and weight loss in obese asthma
patients should be recommended, thereby promoting a
healthy lifestyle which is likely to improve the quality
of life for the asthmatic [46,148]. Other co-morbid con-
ditions, particularly rhinitis, should be recognized and
treated [46,149]. If rhinitis is associated with nasal
polyposis and aspirin intolerance, non-steroidal anti-
inflammatory agents should be avoided, as they may
cause severe bronchoconstriction [150]. Gastroesophageal
reflux disease (GERD) should also be considered a poten-
tial cause of worsening asthma symptoms although its
effects are quite variable within patients [149].
Pharmacological
Drugs frequently prescribed for cardiovascular conditions
such as β-blockers, even in the form of eye drops for con-
ditions such as glaucoma, can induce bronchoconstriction
and their use should be reviewed and avoided in asthmatic
patients, when these medications can be shown to worsen
asthma control [151].
Although there is a lack of studies on the specific effects
of current asthma medications in this population, these
patients being often excluded from clinical trials, it is
nevertheless recommended that treatment should focus
on control of airway inflammation as in other asthmatic
populations [151-153]. Inhaled corticosteroids (ICS) are
the mainstay of asthma treatment and we have no reason
to think their efficacy/safety profile should be different in
the elderly population. However, there have been reports
of underuse of this type of treatment in the elderly [152].
Local side-effects, such as dysphonia and oral candidiasis
can be reduced by using a spacer with the metered-dose
inhaler and by mouth rinsing after use. Oral corticoste-
roids use should be minimized to avoid worsening of
commonly associated conditions such as osteopenia, dia-
betes and systemic hypertension [21].
Regarding leukotriene antagonists, although we have few
data on their effects in the elderly asthmatic patient, they
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second-choice anti-inflammatory drug after ICS, or as add-
on therapy [21,154,155]. In this population in particular,
each treatment should be considered as a therapeutic trial
of size one, and its effects well documented.
The first choice as acute reliever therapy remains an
inhaled fast-acting β-adrenergic agonist. It is however
even more important in elderly patients to minimize their
use as these agents can induce troublesome side-effects
such as tremor, tachycardia, or arrhythmias [155]. The
sometimes associated reduction in serum potassium and
electrocardiographic changes in QT interval may be of
concern in cardiac patients, although rarely significant.
Long-acting β-adrenergic agonists can be used in associ-
ation with ICS to improve asthma control in more than
mild severity asthmatics, and are usually well tolerated at
usual doses although in some patients the doses should be
reduced if side-effects are troublesome.
Anticholinergics such as tiotropium are well tolerated
in the elderly, but we need more studies about their role
in geriatric asthma [156]. They may be considered as add-
on therapy to ICS, particularly if long-acting β-adrenergic
agonists are not well tolerated. Inhaler technique should
be carefully checked and the type of inhaler prescribed
may be reassessed if there are some difficulties with its
use, for example in cases of severe arthritis, dental
problems and general incoordination, or insufficient
inspiratory flows.
Nowadays, theophylline are rarely considered in asthma
therapy and its use can even be more problematic in the
elderly, due to drug interactions and the high potential of
side-effects such as arrhythmia.
Asthma education and treatment adherence
Provision of adequate asthma education is particularly
important in the elderly due to the often complex treat-
ments, co-morbidities and sometimes reduced memory
and cognitive functions [142,157,158]. Poor treatment
adherence, inappropriate inhaler use, or depression were
found to be independent predictors for asthma exacerba-
tion in the elderly [158]. An important benefit of education
could be in improving adherence to treatment and im-
proving self-management skills. In this regard, adherence
to therapy has been often reported as deficient in the
elderly. Frequent patient follow-up visits and monitoring
for medication adherence, including proper inhalation
technique is encouraged. Some patients may also find it
difficult to implement a written action plan in the event
of an acute exacerbation, and the immediate availability
of an asthma educator (by phone or in person), would be
ideal [159-161]. The technique of device inhaled medication
administration is a difficult problem in elderly patients, and
the great majority of elderly patients can not properly use
the inhaler, even after the proper instruction [162,163]. Theuse of dry powder devices, although easy to use, requires
the generation of an adequate inspiratory flow can be
sub-optimal in fragile patients and those with severe
airway obstruction. In such situations, the use of spacers
or nebulizer devices may be beneficial. Patients should
recognize the rationale behind the use of different drugs,
the correct way to use them, and their side effects and
polypharmacy with more devices should also be avoided.
Pulmonary rehabilitation
Pulmonary rehabilitation is mostly recommended for pa-
tients with COPD, but some asthmatic patients, particu-
larly when they suffer from the asthma-COPD “overlap
syndrome”, may potentially benefit from such program.
As exercise is of importance in asthma and COPD, such
program may promote active physical activity in this
group and previous studies have suggested that this could
improve asthma control [164-167].
Summary and conclusions
There is agreement that AIE is both a common and an
under-recognized health problem for the elderly that
leads to impairments of lung function and quality of
health and life, which is understudied and frequently
underdiagnosed and undertreated. There are data to
suggest that asthma in older adults is phenotypically
different from young patients, with potential impact on
the diagnosis, assessment and management in this popula-
tion. The diagnosis of AIE in older populations relies on
the same clinical findings and diagnostic tests used in
younger populations, but the interpretation of the clinical
data is more challenging. The possibility of multiple
causes of symptoms or physical dysfunction is more
likely in the aged. The response to drugs may also be less
interpretable. There are several reasons why a physician
should strive to make a specific diagnosis for a patient
presenting with a symptom complex. Just providing the
patient with a disease diagnosis or label can be reassuring
to the patient. Moreover, advancement of understanding
of the epidemiology, natural history, pathobiology, and
treatment require a definable disease entity. Whether the
threshold for diagnostic criteria is set at a high level of
sensitivity, a high level of specificity, or a high level of
accuracy depends entirely upon the costs and benefits
of an incorrect diagnosis vs. a missed diagnosis.
We need additional information concerning the natural
history of physiologic changes in the asthmatic lung with
aging, including the development of irreversible airflow
obstruction. Furthermore, we need more research to de-
termine if making a clear-cut distinction between asthma
vs. COPD in the elderly is important either for prognosis
or treatment decisions.
We need better methods, e.g., biomarkers, and tools to
help differentiate asthma from other causes of obstructive
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understand the changes in lung physiology which occur
with aging, they will find that it easier to evaluate the older
patient who presents with lower airway obstruction.
The challenge today is to encourage new research in
AIE but to use the existing knowledge we have to make
the diagnosis of AIE, educate the patient, develop a thera-
peutic approach to control the disease, and ultimately
provide a better quality of life to our elderly patients.Competing interests
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